Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 1"
topic_facet:"Medical Condition: Melanoma MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Melanoma+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10053571Term%3A+MelanomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Melanoma+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10053571Term%3A+MelanomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Melanoma+MedDRA+version%3A+21.1Level%3A+LLTClassification+code+10053571Term%3A+MelanomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (14)
1
Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D - Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B - Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D - Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B - Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C - Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B - Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D - Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C - Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B - Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM : A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D - Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 naïve or PD-1 exposed participants with MBM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Phase: Phase 1
Filter aufheben
Thema: Medical Condition: Melanoma MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
14
Aufsätze
14
E-Artikel
14
E-Ressourcen
Zeitschriftentitel
14
WHO International Clinical Trials Registry Plat...
Thema
14
610
Medical Condition: Melanoma MedDRA version: 21....
Phase: Phase 1
14
Recruitment Status: Authorised-recruitment may ...
14
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2022
10
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
14
Englisch
Haven't found what you're looking for?
Wird geladen...